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Abstract
Genome-wide association studies in human populations have facilitated the creation of genomic profiles which combine the
effects of many associated genetic variants to predict risk of disease. The area under the receiver operator characteristic
(ROC) curve is a well established measure for determining the efficacy of tests in correctly classifying diseased and non-
diseased individuals. We use quantitative genetics theory to provide insight into the genetic interpretation of the area under
the ROC curve (AUC) when the test classifier is a predictor of genetic risk. Even when the proportion of genetic variance
explained by the test is 100%, there is a maximum value for AUC that depends on the genetic epidemiology of the disease,
i.e. either the sibling recurrence risk or heritability and disease prevalence. We derive an equation relating maximum AUC to
heritability and disease prevalence. The expression can be reversed to calculate the proportion of genetic variance explained
given AUC, disease prevalence, and heritability. We use published estimates of disease prevalence and sibling recurrence risk
for 17 complex genetic diseases to calculate the proportion of genetic variance that a test must explain to achieve
AUC=0.75; this varied from 0.10 to 0.74. We provide a genetic interpretation of AUC for use with predictors of genetic risk
based on genomic profiles. We provide a strategy to estimate proportion of genetic variance explained on the liability scale
from estimates of AUC, disease prevalence, and heritability (or sibling recurrence risk) available as an online calculator.
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Introduction
Genome-wide association studies in human populations have
facilitated the creation of genomic profiles which combine the
effects of many associated genetic variants to predict risk of
disease. Genetic testing has long been available for Mendelian
genetic diseases for which variants within one gene are directly
responsible for the disease. In contrast, the etiology of complex
genetic diseases, such those listed in Table 1, comprises both
genetic and environmental risk factors. Results from genome-wide
association studies have provided empirical evidence that very few
associated genetic variants with effect size greater than odds ratio
of 1.5 exist [1,2]. Reconciliation of these effect sizes with the, often
sizeable, estimates of heritability for many complex diseases
(Table 1) means that we must expect there to be many (perhaps
thousands) of genetic variants underlying complex disease if the
effect size of any one variant is very small. It follows that each
individual will carry a different, probably unique, portfolio of risk
alleles. Whereas common risk variants have size too small to be
used individually as risk predictors, profiles based on many
associated genetic variants could provide useful predictions of
genetic risk [3,4]. We define genetic risk as the risk of disease given
an individual’s unique multi-locus genotype; genetic risk remains
unchanged throughout an individual’s lifetime and so could be
predicted at birth prior to exposure to many environmental risk
factors. Indeed, such risk predictions could be age specific, for
example, risk of type 2 diabetes at 10 years, 20 years or 50 years if
genomic profile sets based on empirical data were available for
these scenarios which have age-specific genetic epidemiologies. As
more variants are identified in the coming years, there will be
increasing interest in the prospects of genomic profiling. It has
been argued that genomic profiles should be assessed in terms of
their clinical validity as diagnostic classifiers [5,6]. The receiver
operator characteristic (ROC) curve [7] is a well established tool
for determining the efficacy of clinical diagnostic and prognostic
tests in correctly classifying diseased and non-diseased individuals
and has been used in the context of genomic profiling e.g., [6,8,9].
While the area under the ROC curve (AUC) is an important
measure for clinical validity it does not tell the whole story as it
does not differentiate between the accuracy with which the
genomic profile predicts the true genetic risk of individuals and the
accuracy with which true genetic risk predicts disease status, which
is not under our control. We believe that the ability to differentiate
between these components (i.e. the distinction between prediction
of genotype and phenotype) is important for interpretation of the
value of the genomic profile, particularly as the use of genomic
profiles is very much in its infancy at present. Our knowledge of
the genetic epidemiology of a disease means that we can know a
priori that genomic profiles might not, on their own, be accurate
diagnostic classifiers. For this reason, genomic profiles should
judged in the first instance on the basis of their analytic validity
[10] as predictors of genetic rather than absolute risk. Of course, in
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mental risk factors to predict absolute risk in the context of clinical
utility. Genomic profiles should improve upon family history
which has long been used as a crude estimate of genetic risk (see
Text S1).
In this paper, we provide insight into the genetic interpretation of
AUC. We begin by considering quantitative traits for which the
concepts of accuracy of risk prediction are well developed. For
disease traits we differentiate between measures on the observed
scale of disease versus the underlying scale of disease risk as we
believe recognition of scale of measurement is often overlooked. We
define AUCmax as the maximum AUC that could be achieved for a
disease when the test classifier is a perfect predictor of genetic risk.
We quantify the relationship between AUCmax and heritability of
liability and disease prevalence (lifetime morbidity risk). We show
how to interpret AUC (which is a measure on the observed disease
scale) of a genomic profile as the proportion of variance explained
(or accuracy of prediction squared) on the underlying liability scale.
Finally, we benchmark the value of genomic profiles by comparing
them to the AUC expected when family history resulting from
shared genetic risk factors is used as a predictor of genetic risk.
Methods
Background: quantitative traits
For quantitative traits, in which phenotypic scores are (or can be
transformed to be) normally distributed, the efficacy of a genomic
profile is naturally expressed as the proportion of the genetic
variance explained by the profile. The variance in phenotypes, VP,
can be partitioned into variance of genetic values, VG, so that the
proportion of the variance that is genetic is the heritability VG/VP.
Genomic profiling provides a direct estimate, ^ G G, of true genetic
values, G, for individuals in a population and the efficacy of a
genomic profile can be expressed as the proportion of the genetic
variance explained by the profile V ^ G G/VG. We define r2
^ G GG =V ^ G G/
VG, since in selection theory [11], used in livestock and plant
breeding, the correlation between predicted and true genetic risk
(r^ G GG) is used as the measure of accuracy of prediction,
r^ G GG~
Cov ^ G G,G
  
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
V^ G GVG
p , and if the predictor is unbiased (the regression
of G on ^ G G is 1), r^ G GG~
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
V^ G G=VG
p
. The ratio V ^ G G/VP is estimated as
the R
2 from the regression of P on ^ G G and is interpreted recognising
its upper limit to be VG/VP or heritability. These measures show
that for quantitative traits, the accuracy with which the genomic
profile predicts genetic risk is clearly separable from accuracy with
which the true genetic risk predicts the phenotype. In contrast,
AUC is a measure of the efficacy with which ^ G G predicts phenotype
which, as shown below, has an upper limit constrained by the
heritability, and also prevalence, of the disease.
Background: disease traits
For disease traits, the phenotype has two possible values, either
affected or not affected. On this observed scale, the directly
measurable genetic parameters are those of recurrence risks to
relatives, lR for relatives of type R, which is the ratio of the
prevalence of disease in the relatives of affected individuals (KR)
compared to the prevalence in the population (K),
lR~
KR
K
~1z
cov X,R ðÞ
K2
where cov(X, R) the covariance in disease status between diseased
individuals X and their relatives on the observed disease risk scale
[12]. For example, when the relatives are monozygous twins
(R=MZ), Cov(X,MZ)=VG01 the genetic variance, with the
subscript ‘‘01’’ denoting the all-or-none disease risk scale. On this
scale, the majority of the genetic variance is non-additive,
especially when disease prevalence is low [13,14]. The broad
sense heritability on this scale is H2
01 =(lMZ -1)K/(1-K) where
lMZ is the monozygotic twin recurrence risk, assuming there
is no common environmental component to the recurrence
risk. H2
01 is not a normally reported statistic because of its
dependence on disease prevalence [15]. If the relatives
are siblings (R=S)t h e nlS is the sibling risk ratio and
Cov(X,S)=
VA01
2
z
VD01
4
z
VAA01
4
z
VAD01
8
z
VDD01
16
z
VAAA01
8
z
VAAD01
16
z... [11], where the variance subscripts A and D denote
additive and dominance terms, and in combination denote epistatic
variance terms. Thus, although lS is an estimable quantity, it is not
simply related to the genetic variances on the observed binary scale.
The genetic properties of disease are much more easily
understood by using the threshold liability model [11], in which
risk of disease is transformed to a normally distributed liability
scale P ,N(0, 1) and P=A + E, where A,N(0, h2
L) are the genetic
effects on the liability scale. On this scale the genetic effects
combine in an additive way; h2
L is the narrow sense heritability on
the liability scale (or heritability of liability) and on this scale broad
sense and narrow sense heritability are equal. E are independent
environmental effects, E,N(0,1-h2
L). The biological plausibility of
an underlying normally distributed liability to disease is based on
the assumption that complex traits are influenced by many
variables; the central limit theorem states that the distribution of
the sum of independent random variables approaches normality as
the number of variables increases. Under the threshold liability
model individuals are affected when P .T, where T is the
threshold on the normal distribution which truncates the
proportion of affected individuals or disease prevalence (i.e., K),
T=W
21(1-K), W(T)=1-K, where W(T) is the cumulative density
function of the normal distribution up to values of T, e.g. if
K=0.05, T=1.645. The threshold liability of risk scale has much
nicer properties than the observed disease scale and provides a
framework for comparison of scenarios independent of disease
prevalence. The relationship between heritability of liability h2
L
and the directly estimable parameters of K and lS is
h2
L~
2 T{T1
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
1{ T2{T2
1
  
1{T=i ðÞ
q hi
izT2
1 i{T ðÞ
ð1Þ
[16] with i~z=K and z the height of the standard normal curve
and T1=W
21(1- lS K), i.e. the threshold T1,T when lS.1,
Author Summary
Genome-wide association studies in human populations
have facilitated the creation of genomic profiles that
combine the effects of many associated genetic variants to
predict risk of disease. However, genomic profiles are
inherently constrained in their ability to classify diseased
from non-diseased individuals dictated by the genetic
epidemiology of the disease. In this paper, we use a
genetic interpretation to provide insight into the con-
straints on genomic profiles for risk prediction. We provide
a strategy to estimate proportion of genetic variance
explained on the liability scale from estimates of AUC,
disease prevalence, and heritability available as an online
calculator.
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KS is greater than the prevalence in the population as a whole (e.g.
if K=0.05 and lS=2,z=0.103, T1=1.282, h2
L =0.371).
Area under the ROC curve
The AUC is a statistic calculated on the observed disease scale and
is a measure of the efficacy of prediction of phenotype using a test
classifier. The ROC plots the true positive rate (TPR or sensitivity)
against the false-positive rate (FPR or 1-specificity). TPR =proba-
bility (positive test result|diseased) and FPR = probability (positive
test result|not diseased). Since these probabilities are conditional,
they are not dependent on the number of cases or controls tested,
except through the sampling variance associated with them. In
genomic profiling the ROC is obtained by ranking a set of
individuals with known disease status by their genomic profile from
lowest estimated risk (i.e., profile score) to highest estimated risk
and then assessing sensitivity and specificity assuming a cut-off after
each rank (starting with the highest ranked individual). If nd and nd’
are the numbers of diseased and not diseased individuals, and
if the individual with the highest predicted genetic risk has rank
r1=nd + nd’=n, AUC can be calculated directly from the mean rank
of the diseased individuals (  r rd),
AUC~
1
nd0
  r rd{
nd
2
{
1
2
  
ð2Þ
(see example in Figure S1). Equally, AUC can be calculated as
AUC=0.5(1 + D)w h e r eD is the Somers’ rank correlation [17]
between risk profile and disease status (1= diseased, 0= not
diseased). Another equivalent definition of AUC is the probability
that a randomly selected pair of diseased (d) and non-diseased (d’)
individuals are accurately classified [18]. The probability is the same
as the probability that difference between the genetic liability of the d
and d’ individuals is greater than zero. This difference is
approximately normally distributed with mean md - md’ and variance
s2
d z s2
d0. Using the liability threshold model and results of standard
genetic selection theory [11] the means (m)a n dv a r i a n c e s( s
2)o ft h e
genetic liability of d and d’ individuals are
md~ih2
L,
md0~vh2
L,
s2
d~h2
L 1{h2
Lii {T ðÞ
  
,
s2
d~h2
L 1{h2
Lii {T ðÞ
  
,
where v=-iK/(1 – K). The genetic liabilities of the d and d’ groups are
each approximately normally distributed, the approximation being
less accurate for high heritabilities.
Therefore,
AUCmax~Pr md{md0w0 ðÞ &
W
i{v ðÞ h2
L ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
h2
L 1{h2
Lii {T ðÞ
 
z 1{h2
Lvv {T ðÞ
     q
0
B @
1
C A
ð3Þ
Using AUC measured by a genomic profile to estimate
the proportion of genetic variance explained
A useful property of AUC (as discussed above) is that for a given
disease the estimated AUC is independent of the relative
proportions of cases and controls in the sample being classified
[7], i.e. the mean rank is approximately the same if the proportion
of cases: controls is K: (1-K) or 1:1. Or equally, the probability of a
randomly selected case and control being correctly ranked is
independent (except for sampling) of the number of cases and
controls measured. We can use equation 3 to estimate the variance
on the liability scale explained by a genomic profile, x, by making
h2
L the subject of the equation, but renaming it as h2
Lx ½  , recognising
that it represents the proportion of variance explained by the
profile. Then, from two measurable parameters, K and AUC,w e
can calculate h2
Lx ½  ,
h2
Lx ½  ~
2Q2
v{i ðÞ
2zQ2ii {T ðÞ zvv {T ðÞ
   , ð4Þ
Where Q=W
21(AUC). From this, we can calculate the
proportion of the known genetic variance explained by the
genomic profile
r2
^ G GG~h2
Lx ½  =h2
L ð5Þ
using the estimates of K and lS to calculate h2
L (equation 1). We can
also calculate the proportion of the sibling risk explained by the
profile, (lS[x] – 1)/(lS – 1), where lS[x]=(1-W(T1[x]))/K and
T1 x ½  ~
T{h2
Lx ½  i=2
  
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
1{h4
Lx ½  ii {T ðÞ =4
q ð6Þ
[19]. r2
^ G GG and (lS[x] – 1)/(lS – 1) measure the same concept but in
different ways and on different scales; both are useful criteria for
assessing the extent to which the genomic profile accounts for the
known genetic component of disease. We consider family history
as a predictor of genetic risk in the Text S1.
Simulation
We used simulation under the liability threshold model [11,14]
to check our derivations. We simulated 100,000 nuclear families
sampling risk on the liability scale, P=A + E, A , N(0, h2
L) for
parents, and A=KAdad+KAmum+Amend for children, where the
Mendelian segregation terms were random numbers sampled as
Amend , N(0, Kh2
L); E , N(0,1 - h2
L). Individuals were considered
affected, P01=1, if P .W
21(1-K)=T, otherwise individuals were
not affected and P01=0. Genetic values on the observed scale, G01,
were calculated as the normal probability, G01~W
A{T
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
1{h2
L
q
0
B @
1
C A.
From this we could calculate VG01, VP01, H2
01~VG01=VP01(using the
G01 and P01 of the first child from each family) and sibling
recurrence risk. AUCmax was calculated from the mean rank of
diseased individuals using equation 2 when ranked on A.
Results
The maximum value of AUC when the test classifier is a
genetic predictor depends on heritability and disease
prevalence
In Figure 1A we consider two diseases both with heritability of
liability, h2
L =0.2, plotting probability of disease (i.e. G01) vs genetic
liability (i.e. A). To allow an extreme comparison, one of the
diseases has prevalence K=0.5 and the other, K=0.01. Figure 1B
ð3Þ
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in this case both have h2
L =0.8. In Figure 1A and 1B, the position
of the rise in probability of disease along the x-axis reflects the
disease prevalence and the steepness of the rise reflects the
heritability of the disease. In Figure 1A the distribution of genetic
liabilities on the underlying scale is exactly the same for these two
diseases, but when K=0.01 higher genetic liabilities are needed
before probability of disease rises above virtual zero (virtual
because it is not exactly zero, but very close to zero); similarly for
the diseases in Figure 1B. Figure 1C and 1D plot the ROC curves
for the diseases considered in Figure 1A and 1B, respectively.
These graphs demonstrate firstly (not unexpectedly), that for
diseases with the same prevalence, genetic liability is a better
predictor of disease status for diseases with higher heritability and
secondly, that for diseases with the same heritability, genetic
liability is a better predictor of disease status for rarer diseases,
because a higher proportion of those with high genetic liability are
actually diseased. For example, if we used genetic liability of $1a s
our predictor of disease, then the TPR is 0.26 and the FPR=0.00,
when K=0.5, compared to TPR=0.99 and the FPR=0.12, when
K=0.01. These graphs demonstrate that maximum value of AUC
(i.e. AUCmax) when the test classifier is a genetic predictor is
dependent on both h2
L and K.
Prediction of AUCmax from h2
L (or lS) and K
Figure 2 plots AUCmax vs h2
L,f o rK=0.001, 0.01, 0.1, 0.3 from
simulation (dashed line) and from equation 3 (solid line) and
shows that AUCmax is particularly constrained for more common
or low heritability diseases. Jannsens et al [3], in their Fig. 4, have
shown the relationship between AUC and the proportion of
variance on the disease scale explained by the genomic profile;
since their genomic profile assumed all genetic variants were
known without error their graph represents the relationship
between AUCmax and H2
01. Our simulation results provided the
same relationship when plotted on this scale (Figure 3, solid line).
In Figure 3 we show the relationship of AUCmax with H2
01 and h2
L
(for each simulation combination of K and h2
L,t h eAUCmax and
H2
01 are calculated).
Figure 1. The dependence of maximum AUC (AUCmax) from a genomic profile on heritability and disese prevalence. (A,B) Probability of
disease versus genetic liability. (C,D) ROC curve [46].
doi:10.1371/journal.pgen.1000864.g001
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Table 1 lists AUCmax for a range of complex genetic diseases
calculated using equation 3, with h2
L calculated using equation 1
from published estimates of K and lS. Despite being observable,
the parameters K and lS are subject to considerable sampling
variance; we have tried, where possible, to take estimates from
reviews or large studies, but large study samples simply do not
exist for some low prevalence disorders. The values of AUCmax
show that it should be possible for a genomic profile for complex
diseases to exceed 0.75, the threshold regarded [20] as making a
diagnostic classifier clinically useful when applied to a sample
considered to be at increased risk. However, based on the results
in Table 1 only the diseases with high heritability and low
prevalence, such as Type I diabetes, Crohn’s Disease and Lupus,
can achieve an AUC, by genomic profiling alone, above the 0.99
threshold regarded [20] as being required for a diagnostic
classifier to be applied in the general population. In Table 1, we
also consider the AUC expected under scenarios where a
genomic profile accounts for only a half (AUChalf) or a quarter
(AUCquar) of the known genetic variance. These results show that
for rare diseases genomic profiles can be useful classifiers of
disease (AUC.0.8 when K,0.01), when the profile explains only
a quarter of the genetic variance.
Using equations (4) and (5) we calculate r2
^ G GG for the diseases
listed in Table 1 when AUC=0.75. The results (Table 1) show
that the same AUC can represent quite different successes of the
genomic profile in representing the known genetic variance,
ranging from 0.10 to 0.74. If we are able to explain half of the
known genetic variance with identified risk variants then genomic
profiles for most complex genetic disease (AUChalf, Table 1) will
achieve some clinical validity as AUC is .0.75 for all but bladder
cancer, for the examples provided.
Example: age related macular degeneration
Consider the first listed example in Table 1, age related macular
degeneration (AMD).
Based on the review of Scholl et al [21] and the large twin study
of Seddon et al [22] we have used a prevalence after 80 years age
of advanced AMD K=11.8% and a sibling recurrence risk
representing the genetic contribution of lS=2.2, which corre-
spond to heritability on the liability scale of h2
L =0.68 (equation 1).
If the genetic test explains all the genetic variance (r2
^ G GG =1), the
maximum AUC that could be achieved by a genomic profile is
AUCmax=0.92. If only half or a quarter of the genetic variance can
be detected by genomic markers then the maximum AUC that can
achieved are AUChalf=0.81 and AUCquar=0.72, respectively,
values that exceed the prediction of genetic risk based of the most
optimistic scenario from a prediction based on family history (Text
S1). If complete disease status is known for all siblings, parents,
grandparents, aunts, uncles and cousins then the maximum AUC
that could be achieved is 0.71, translating to a genomic profile that
explains 0.21 of the genetic variance (Table S1). In practice, the
AUC for a risk predictor based on rs1061170 a single nucleotide
polymorphism in the complement factor H (CFH) gene was 0.69
[23] (and was approximately equal for advanced AMD cases vs
controls and all AMD cases vs controls). From equations 4–6,
h2
Lx ½ =0.12, lS[x]=1.17, r2
^ G GG =0.17 and (lS[x] – 1)/(lS – 1)=0.15.
Discussion
Relationship of AUCmax to heritability and disease
prevalence when the disease classifier is a genetic risk
predictor
The AUC is a widely used statistic that summarises the clinical
validity of a diagnostic or prognostic test. However, the AUC
statistic of a genomic profile alone has an upper limit (i.e. AUCmax)
which depends on the genetic epidemiology of the disease, namely
the disease prevalence and heritability. It is important that in the
first instance, particularly when genomic profiling is in its infancy,
that genomic profiles are judged on their ability to predict genetic
risk (their analytic validity) rather than on the basis of clinical
Figure 2. Relationship between maximum AUC (AUCmax) from a
genomic profile and heritability on the liability scale h2
L. For
different disease prevalences (A–D) from simulation (dashed line) and
from equation 3 (solid line).
doi:10.1371/journal.pgen.1000864.g002
Figure 3. The relationship between maximum AUC (AUCmax)
from a genomic profile and heritability on the liability scale h
2
L
(dashed line) or heritability on the observed scale H2
01 (solid
line), for disease prevalences in order from top left, K=0.001,
0.01, 0.1, 0.3.
doi:10.1371/journal.pgen.1000864.g003
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correlation its genetic interpretation is not immediately obvious.
Here we provide a genetic interpretation of the AUC expressed in
terms of it genetic epidemiology parameters (equation 3). A
relationship between AUCmax and heritability was first demon-
strated graphically by Janssens et al [3] (see solid line Figure 3).
However, their representation was of broad sense heritability on
the observed scale (i.e. H2
01) which is a little used measure of
heritability because of its dependence on disease prevalence [13].
Here we show (Figure 2 and equation 3) the relationship between
AUCmax and the more commonly used measure of heritability, the
heritability of liability (i.e., h2
L) We show that AUCmax is dependent
on both h2
L and disease prevalence (i.e. K).
Initially, it may seem counter-intuitive that AUC depends on
disease prevalence since for an individual disease TPR and FPR
are independent of the proportion of cases and controls measured
and therefore of the sample prevalence. However, as we have
clearly shown (Figure 1A and 1B) the dependence on disease
prevalence results from our ability to generalise across diseases in
the context of a test classifier being a genomic profile.
In contrast to our results and those of Janssens et al [3], Clayton
[24] provided an expression for ROC under a polygenic model
which is independent of population disease prevalence. His
derivation assumes that the effect of each locus is additive on
the log risk scale [25]. Slatkin [26] and we [27] have found that
this model allows probabilities of disease that exceed one, which
although they occur with low frequency can have substantial
impact on the estimates of recurrence risk and genetic variance.
Under this model there is a relationship between recurrence risk to
monozygotic twins and to siblings of lMZ/l
2
S =1; this ratio is not
achieved when probabilities of disease are constrained to their
natural parameter space of a maximum of 1. Furthermore,
empirical estimates of the ratio of lMZ/l
2
S from the studies listed in
Table 1 that provide estimates of lMZ and lS are mostly less than
1.0 [27], particularly for low prevalence diseases. Recognising that
these estimates are subject to sampling variance, the estimates of
lMZ/l
2
S are 1.1 (AMD), 0.4 (coronary artery disease), 0.8 (breast
cancer), 0.7 (schizophrenia [25]), 0.9 (rheumatoid arthritis) and 0.4
(Type I diabetes). Therefore, we believe the model used by
Clayton to derive the relationship between AUC and heritability
(or sibling recurrence risk) independent of disease prevalence is not
valid.
AUC and accuracy of genetic profiles
AUC is a useful measure because of its independence of the
numbers of diseased and diseased individuals tested, but we
advocate the reporting of an estimate of the proportion of the
known genetic variance on the liability scale (r2
^ G GG) or the
proportion of sibling risk accounted for by the profile and we
provide a method to do this using the estimated AUC, disease
prevalence and heritability on the liability scale or sibling
recurrence risk (equation 5). An AUC of 0.75 can imply anything
from 0.10 to 0.74 of the genetic variance explained by the genomic
profile for the complex diseases listed in Table 1. The correlation
r^ G GG has long been the benchmark in non-human genetics of
accuracy of genetic risk predictors. r2
^ G GG can be calculated from
three measurable statistics, disease prevalence, sibling recurrence
risk and AUC of the profile (using equations (1) and (4)). In this
way, estimates of AUC can provide direct estimates of the
proportion of ‘missing heritability’ [28] which takes into account
the interdependence of identified associated variants.
Currently, the derivation of genomic profiles is very much in its
infancy. As the sample size of genome-wide association studies
increase, we can expect genomic profiles to include more and
more validated associated variants. However, r2
^ G GG is constrained
by the variance that could be detected by the markers that are
genotyped recognising that the current generation of genome-wide
chips explain at most ,80% of the known variance in single
nucleotide polymorphisms across the Caucasian genome [29].
This, in turn, may only be a fraction of the total genomic variance
once structural variants such as copy number variants are included
[30]. The actual variance explained by the profile depends on the
sample size (i.e., power) of the studies from which associated
genetic variants have been detected. It is likely that there are many
variants which have such a small effect size that they will be
impossible to detect even with very large samples. Although each
such variant makes only a very small contribution to the genetic
variance, there may be so many that a sizeable proportion of the
variance will go undetected. Even if only quarter of the genetic
variance is detectable by our future genotyping technology, the
AUC is still greater for the genomic profile than for family history
(ignoring shared environmental risks of family members, Text S1).
Limitations
In our derivations we have assumed the liability threshold
model [11,14]. Slatkin [26] demonstrated that the threshold model
was one of several genetic models that provided the necessary
steep increase in probability of disease with increasing load of
genetic risk alleles [26]. The main assumption of the liability
threshold model is that the distribution of liability scores is
unimodal which should be achieved as long as there is no single
unidentified genetic or environmental of very large effect [11].
The model accommodates any distribution of risk allele effect sizes
and risk allele frequencies as long as there are sufficient (‘‘more
than one or a few’’ [11]) risk alleles in the population to create an
approximately normal distribution of genetic liability scores. Since
our simulation results of AUCmax vs H2
01 (Figure 3) based on the
liability threshold model agree with those of Janssens et al [3] who
used a logit model to combine genetic risks from individual genetic
variants, it is clear that the dependence of AUCmax on heritability
and disease prevalence is not a function of the threshold model.
We have also assumed that a genetic profile is applied in the
same ‘‘average’’ environment as the genetic risks were estimated
and we have assumed that all familiality is of genetic origin. The
AUCmax will be lower than those derived here if any part of the
sibling recurrence risk reflects co-variation of non-genetic origin.
Using recurrence risks from different types of relatives, the
importance of common environmental factors can be assessed
and a lS which reflects the genetic contribution of sibling
recurrence can be used in our calculations. We have also assumed
that the genomic profile consists of genetic markers associated with
disease that are passed on according to the rules of Mendelian
inheritance. In the future, a genomic profile might include non-
heritable genetic variants, for example recurrent de novo copy
number variants or perhaps methylation status variants (for which
the inheritance pattern, if any, is currently unclear [31]). Such
variants, although genetic, do not contribute to the similarity
between relatives, and so would be included in the environmental
component when partitioning variance. Under these circumstanc-
es it is possible that a genomic profile could exceed the AUCmax
based on sibling recurrence ratio. Our calculations assume that we
know the population parameters K and lS (and therefore h2
L).
Estimates of these parameters are sometimes based on small
sample size and are subject to sampling bias or different definitions
of the disease. In particular, prevalence rates can depend on the
age distribution of the population in which they are measured. In
addition, recurrence risk ratios of relatives have a maximum
possible value which is dependent on the disease prevalence, so
Genetic Interpretation of AUC
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lower; and estimates of sibling risk ratio and disease prevalence
calculated in different studies sometimes reflect this dependence.
In Table 1, we included two different estimates for both
schizophrenia and bipolar disorder, but for these examples the
estimates of AUCmax are robust to the magnitude of differences
reported in genetic epidemiology parameters for individual
diseases. At present, genomic profiles based on validated
associated variants do not come anywhere close to the maximum
implied by their AUCmax; Jakobsdottir et al [6] have reported AUC
of 0.80 for risk of cardiovascular events, 0.64 for type 2 diabetes,
0.56 for prostate cancer, 0.66 for Crohn’s Disease and 0.79 for age
related macular degeneration. This is not surprising given the
effect size of individual associated variants discovered in genome-
wide association studies, which imply that much larger sample
sizes will be needed to discover the majority of the variants that
explain the genetic variance [4]. However, already these genomic
profiles outperform family history (resulting from shared genetic
risk only) for four out of five of these diseases. Although the AUC is
a useful summary statistic for clinical validity, in practice clinical
utility depends on many other factors such as the benefits versus
risks of the intervention strategies that follow from the risk
prediction [5,32]; these important factors are not considered here.
Conclusion
We have provided a genetic interpretation of and insight into
the AUC statistic calculated under a genomic profile. Time will tell
if genetic variants amenable to genotyping are able to reconstruct
the known genetic variance in its totality. Even if it is possible to
explain only a quarter of the known genetic variance, the genomic
profile will be a more useful predictor of genetic risk than self-
reported family history (in the absence of shared environmental
risk factors) which is a commonly used measure for targeted
screening programmes for complex genetic diseases. In practice,
predictions of risk to disease will incorporate both genetic and
environmental risk factors to produce the best predictions of
absolute risk to disease. Here we provide a benchmark for the
expected contribution from the genetic component of the
prediction illustrating that the same AUC estimated for different
diseases can imply quite different proportions of genetic variance
explained by the genomic profile, which is often overlooked (e.g.
[5]). Ultimately, genomic profiles may be used without contribu-
tions from environmental risk factors, since the contribution from
the genomic profile can be estimated perinatally, prior to exposure
by many environmental risk factors and when limited family
history of disease is available. Indeed, one purpose of a genetic risk
predictor is to allow individuals to choose to modify their exposure
to environmental risks. We provide a simple online calculator
(http://gump.qimr.edu.au/genroc) to calculate i) the maximum
AUC for a genomic profile of a disease given estimates of disease
prevalence and sibling recurrence risk or heritability of liability, ii)
the proportion of variance explained on the liability scale given an
estimate of AUC from a risk predictor and disease prevalence and
iii) proportion of genetic variance or of sibling risk explained given
an estimate AUC, disease prevalence and sibling recurrence risk
[2].
Supporting Information
Figure S1 Example calculation of ROC curve for a genomic
profile. An example of nd=9 diseased (case) and nd’=10 non-
diseased (control) individuals listed in rank order on a genomic
profile. The area under the curve is calculated from equation 2,
which is derived as the sum of the horizontal rectangles (bounded
by dashed lines) of the ROC plot (solid line) generated by
progressing through the ranked list of individuals: each time the
next ranked individual is not diseased, the ROC line moves along
the x-axis by 1/nd’ and each time the next ranked individual is
diseased the ROC line moves up y-axis by 1/nd. The mean rank
value (ri) of the cases is   r rd =13.2 and AUC=0.82.
Found at: doi:10.1371/journal.pgen.1000864.s001 (0.07 MB TIF)
Table S1 AUC related statistics for complex genetic diseases:
Table 1 with added columns considering family history.
Found at: doi:10.1371/journal.pgen.1000864.s002 (0.10 MB PDF)
Text S1 AUC based on family history as a prediction of genetic
risk.
Found at: doi:10.1371/journal.pgen.1000864.s003 (0.07 MB PDF)
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